Stockscreener 앱 받기
39.91
6.56%
-2.80
시간 외 거래:
39.58
-0.33
-0.83%
전일 마감가:
$42.71
열려 있는:
$43.77
하루 거래량:
1.04M
Relative Volume:
1.05
시가총액:
$4.19B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-6.03%
1개월 성능:
+34.83%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$39.13
$43.98
1주일 범위
$39.13
$47.40
52주 변동 폭
$12.30
$47.40
Metsera Inc Stock (MTSR) Company Profile
명칭
Metsera Inc
전화
(212) 784-6595
주소
3 WORLD TRADE CENTER, NEW YORK
MTSR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
39.91 | 4.46B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-20 | 개시 | Wells Fargo | Overweight |
| 2025-02-25 | 개시 | BofA Securities | Buy |
| 2025-02-25 | 개시 | Evercore ISI | Outperform |
| 2025-02-25 | 개시 | Guggenheim | Buy |
Metsera Inc 주식(MTSR)의 최신 뉴스
What drives Metsera Inc. stock priceAccelerated investment success - Autocar Professional
Metsera price target raised to $45 from $38 at BofA - TipRanks
What analysts say about Metsera Inc. stockHigh-velocity gains - Autocar Professional
Metsera Inc. Stock Analysis and ForecastGame-changing capital returns - Autocar Professional
Metsera, Inc.: Buy Rating Affirmed Amid Promising Clinical Data and Strategic Positioning - TipRanks
Is Metsera Inc. a good long term investmentExplosive trading opportunities - jammulinksnews.com
ATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit… - RTTNews
Metsera soars 75% after InvestingPro’s April undervalued signal By Investing.com - Investing.com South Africa
Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association - MSN
Why Metsera Inc. stock attracts strong analyst attentionFast Gains With Reduced Risk - Newser
What makes Metsera Inc. stock price move sharplyLow Risk Profit Ideas - Newser
How Metsera Inc. stock performs during market volatility2x Return Forecast - Newser
Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why - sharewise.com
Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Yahoo Finance
Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Yahoo Finance
Metsera, Inc.(NasdaqGS: MTSR) added to S&P Biotechnology Select Industry Index - MarketScreener
Metsera (NASDAQ:MTSR) Now Covered by Analysts at Wells Fargo & Company - Defense World
Metsera stock initiated at overweight by Wells Fargo on obesity drug - Investing.com Nigeria
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results - MSN
Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results - Investing.com Nigeria
Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR) - Seeking Alpha
Cantor Fitzgerald Predicts Metsera FY2026 Earnings - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Metsera Shows Rising Price Performance With Jump To 92 RS Rating - MSN
RFK Axes CDC Vaccine Advisors; Metsera’s Weight Loss Win; FDA Supports CGT - BioSpace
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Metsera (NASDAQ:MTSR) Price Target Raised to $62.00 at Guggenheim - Defense World
Metsera (NASDAQ:MTSR) Shares Gap Up Following Analyst Upgrade - Defense World
Metsera Inc. Stock Soars: What’s Behind the Surge? - timothysykes.com
Metsera stock extends gains on obesity drug data (MTSR:NASDAQ) - Seeking Alpha
Metsera’s obesity candidate ‘comparable to leading GLP-1-based medicines’ - The Pharma Letter
Metsera price target raised to $62 from $56 at Guggenheim - TipRanks
Metsera CEO to Present Obesity Drug Pipeline at Goldman Sachs Healthcare Conference | MTSR Stock News - Stock Titan
Metsera Inc (MTSR) 재무 분석
Metsera Inc (MTSR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):